<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02732015</url>
  </required_header>
  <id_info>
    <org_study_id>2015-0587</org_study_id>
    <secondary_id>NCI-2016-00801</secondary_id>
    <secondary_id>2015-0587</secondary_id>
    <secondary_id>P30CA016672</secondary_id>
    <nct_id>NCT02732015</nct_id>
  </id_info>
  <brief_title>Rolapitant Hydrochloride in Preventing Nausea/Vomiting in Patients With Sarcoma Receiving Chemotherapy</brief_title>
  <official_title>Effects of Rolapitant on Nausea/Vomiting in Patients With Sarcoma Receiving Multi-Day Highly Emetogenic Chemotherapy (HEC) With Doxorubicin and Ifosfamide Regimen (AI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized phase II trial studies how well rolapitant hydrochloride works in preventing
      nausea/vomiting in patients with sarcoma receiving chemotherapy. Antiemetic drugs, such as
      rolapitant hydrochloride, may help control or prevent nausea and vomiting in patients treated
      with chemotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:

      I. To evaluate the effect of rolapitant hydrochloride (rolapitant) on nausea/vomiting in
      patients with sarcoma receiving multi-day highly emetogenic chemotherapy (HEC) regimen of
      doxorubicin and ifosfamide (AI).

      SECONDARY OBJECTIVES:

      I. To evaluate the toxicity of rolapitant in patients receiving AI regimen. II. To evaluate
      the effects of rolapitant on patient reported outcomes.

      OUTLINE:

      PART I: Patients receive dexamethasone intravenously (IV) daily and ondansetron IV on days
      1-5, and rolapitant hydrochloride orally (PO) on day 1.

      PART II: Patients are randomized to 1 of 2 arms.

      ARM I: Patients receive treatment as in part I. Treatment repeats every 21 days for 6 cycles
      in the absence of disease progression or unacceptable toxicity.

      ARM II: Patients receive dexamethasone IV and ondansetron IV on days 1-5, and fosaprepitant
      dimeglumine IV over 30 minutes on days 1 of cycle 2. Treatment repeats every 21 days for 6
      cycles in the absence of disease progression or unacceptable toxicity.

      CHEMOTHERAPY: All patients receive doxorubicin IV over 72 hours, mesna IV, and ifosfamide IV
      over 3 hours on days 1-4 or 1-5. Patients with sarcomas of small cell histology receive
      vincristine sulfate IV on day 1. Cycles repeat every 3 weeks following blood count and
      patient recovery from any acute toxicities.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Terminated per PI's request
  </why_stopped>
  <start_date type="Actual">October 12, 2016</start_date>
  <completion_date type="Actual">July 10, 2020</completion_date>
  <primary_completion_date type="Actual">July 10, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of complete response (CR) of rolapitant hydrochloride administered as a single-dose</measure>
    <time_frame>Up to course 1</time_frame>
    <description>Estimated along with 95% exact confidence interval (CI) of CR rate.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of complete response (CR) of rolapitant hydrochloride versus fosaprepitant dimeglumine</measure>
    <time_frame>Up to course 1</time_frame>
    <description>Fisher exact test will be used to test the difference of CR rates between the two arms. CR rates along with their 95% CIs will be estimated by study arm.
Logistic regression model will be used to assess the effect of patient specific covariates, such as treatment group, gender, etc. on the complete response.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of toxicity</measure>
    <time_frame>Course 1</time_frame>
    <description>Will be graded using the Common Terminology Criteria for Adverse Events version 4.03. Toxicity data will be summarized by frequency tables for all patients and by treatment arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rates in 0-24 hours</measure>
    <time_frame>Up to 24 hours</time_frame>
    <description>Logistic regression models using generalized estimating equations (GEE) will be used to fit the response data to take the intra-patient correlation into account and to compare the differences of the response rates between the two treatment arms and to evaluate the effects of the patient specific covariates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rates in 24-120 hours</measure>
    <time_frame>Up to 120 hours</time_frame>
    <description>Logistic regression models using GEE will be used to fit the response data to take the intra-patient correlation into account and to compare the differences of the response rates between the two treatment arms and to evaluate the effects of the patient specific covariates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rates in 120-240 hours</measure>
    <time_frame>Up to 240 hours</time_frame>
    <description>Logistic regression models using GEE will be used to fit the response data to take the intra-patient correlation into account and to compare the differences of the response rates between the two treatment arms and to evaluate the effects of the patient specific covariates.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Locally Advanced Sarcoma</condition>
  <arm_group>
    <arm_group_label>Arm I (rolapitant hydrochloride)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive treatment as in part I. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity.
CHEMOTHERAPY: All patients receive doxorubicin IV over 72 hours, mesna IV, and ifosfamide IV over 3 hours on days 1-4 or 1-5. Patients with sarcomas of small cell histology receive vincristine sulfate IV on day 1. Cycles repeat every 3 weeks following blood count and patient recovery from any acute toxicities.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (fosaprepitant dimeglumine)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive dexamethasone IV and ondansetron IV on days 1-5, and fosaprepitant dimeglumine IV over 30 minutes on days 1 of cycle 2. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity.
CHEMOTHERAPY: All patients receive doxorubicin IV over 72 hours, mesna IV, and ifosfamide IV over 3 hours on days 1-4 or 1-5. Patients with sarcomas of small cell histology receive vincristine sulfate IV on day 1. Cycles repeat every 3 weeks following blood count and patient recovery from any acute toxicities.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (rolapitant hydrochloride)</arm_group_label>
    <arm_group_label>Arm II (fosaprepitant dimeglumine)</arm_group_label>
    <other_name>Aacidexam</other_name>
    <other_name>Adexone</other_name>
    <other_name>Aknichthol Dexa</other_name>
    <other_name>Alba-Dex</other_name>
    <other_name>Alin</other_name>
    <other_name>Alin Depot</other_name>
    <other_name>Alin Oftalmico</other_name>
    <other_name>Amplidermis</other_name>
    <other_name>Anemul mono</other_name>
    <other_name>Auricularum</other_name>
    <other_name>Auxiloson</other_name>
    <other_name>Baycadron</other_name>
    <other_name>Baycuten</other_name>
    <other_name>Baycuten N</other_name>
    <other_name>Cortidexason</other_name>
    <other_name>Cortisumman</other_name>
    <other_name>Decacort</other_name>
    <other_name>Decadrol</other_name>
    <other_name>Decadron</other_name>
    <other_name>Decadron DP</other_name>
    <other_name>Decalix</other_name>
    <other_name>Decameth</other_name>
    <other_name>Decasone R.p.</other_name>
    <other_name>Dectancyl</other_name>
    <other_name>Dekacort</other_name>
    <other_name>Deltafluorene</other_name>
    <other_name>Deronil</other_name>
    <other_name>Desamethasone</other_name>
    <other_name>Desameton</other_name>
    <other_name>Dexa-Mamallet</other_name>
    <other_name>Dexa-Rhinosan</other_name>
    <other_name>Dexa-Scheroson</other_name>
    <other_name>Dexa-sine</other_name>
    <other_name>Dexacortal</other_name>
    <other_name>Dexacortin</other_name>
    <other_name>Dexafarma</other_name>
    <other_name>Dexafluorene</other_name>
    <other_name>Dexalocal</other_name>
    <other_name>Dexamecortin</other_name>
    <other_name>Dexameth</other_name>
    <other_name>Dexamethasone Intensol</other_name>
    <other_name>Dexamethasonum</other_name>
    <other_name>Dexamonozon</other_name>
    <other_name>Dexapos</other_name>
    <other_name>Dexinoral</other_name>
    <other_name>Dexone</other_name>
    <other_name>Dinormon</other_name>
    <other_name>Fluorodelta</other_name>
    <other_name>Fortecortin</other_name>
    <other_name>Gammacorten</other_name>
    <other_name>Hexadecadrol</other_name>
    <other_name>Hexadrol</other_name>
    <other_name>Lokalison-F</other_name>
    <other_name>Loverine</other_name>
    <other_name>Methylfluorprednisolone</other_name>
    <other_name>Millicorten</other_name>
    <other_name>Mymethasone</other_name>
    <other_name>Orgadrone</other_name>
    <other_name>Spersadex</other_name>
    <other_name>TaperDex</other_name>
    <other_name>Visumetazone</other_name>
    <other_name>ZoDex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (rolapitant hydrochloride)</arm_group_label>
    <arm_group_label>Arm II (fosaprepitant dimeglumine)</arm_group_label>
    <other_name>Adriablastin</other_name>
    <other_name>Hydroxydaunomycin</other_name>
    <other_name>Hydroxyl Daunorubicin</other_name>
    <other_name>Hydroxyldaunorubicin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fosaprepitant Dimeglumine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm II (fosaprepitant dimeglumine)</arm_group_label>
    <other_name>Emend for Injection</other_name>
    <other_name>L-785,298</other_name>
    <other_name>MK-0517</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ifosfamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (rolapitant hydrochloride)</arm_group_label>
    <arm_group_label>Arm II (fosaprepitant dimeglumine)</arm_group_label>
    <other_name>Asta Z 4942</other_name>
    <other_name>Asta Z-4942</other_name>
    <other_name>Cyfos</other_name>
    <other_name>Holoxan</other_name>
    <other_name>Holoxane</other_name>
    <other_name>Ifex</other_name>
    <other_name>IFO</other_name>
    <other_name>IFO-Cell</other_name>
    <other_name>Ifolem</other_name>
    <other_name>Ifomida</other_name>
    <other_name>Ifomide</other_name>
    <other_name>Ifosfamidum</other_name>
    <other_name>Ifoxan</other_name>
    <other_name>IFX</other_name>
    <other_name>Iphosphamid</other_name>
    <other_name>Iphosphamide</other_name>
    <other_name>Iso-Endoxan</other_name>
    <other_name>Isoendoxan</other_name>
    <other_name>Isophosphamide</other_name>
    <other_name>Mitoxana</other_name>
    <other_name>MJF 9325</other_name>
    <other_name>MJF-9325</other_name>
    <other_name>Naxamide</other_name>
    <other_name>Seromida</other_name>
    <other_name>Tronoxal</other_name>
    <other_name>Z 4942</other_name>
    <other_name>Z-4942</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (rolapitant hydrochloride)</arm_group_label>
    <arm_group_label>Arm II (fosaprepitant dimeglumine)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mesna</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (rolapitant hydrochloride)</arm_group_label>
    <arm_group_label>Arm II (fosaprepitant dimeglumine)</arm_group_label>
    <other_name>2-Mercaptoethanesulfonate, Sodium Salt</other_name>
    <other_name>Ausobronc</other_name>
    <other_name>D-7093</other_name>
    <other_name>Filesna</other_name>
    <other_name>Mercaptoethane Sulfonate</other_name>
    <other_name>Mercaptoethanesulfonate</other_name>
    <other_name>Mesnex</other_name>
    <other_name>Mesnil</other_name>
    <other_name>Mesnum</other_name>
    <other_name>Mexan</other_name>
    <other_name>Mistabron</other_name>
    <other_name>Mistabronco</other_name>
    <other_name>Mitexan</other_name>
    <other_name>Mucofluid</other_name>
    <other_name>Mucolene</other_name>
    <other_name>UCB 3983</other_name>
    <other_name>Uromitexan</other_name>
    <other_name>Ziken</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ondansetron</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (rolapitant hydrochloride)</arm_group_label>
    <arm_group_label>Arm II (fosaprepitant dimeglumine)</arm_group_label>
    <other_name>Zofran ODT</other_name>
    <other_name>Zuplenz</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm I (rolapitant hydrochloride)</arm_group_label>
    <arm_group_label>Arm II (fosaprepitant dimeglumine)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rolapitant Hydrochloride</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm I (rolapitant hydrochloride)</arm_group_label>
    <other_name>Rolapitant HCl</other_name>
    <other_name>Rolapitant Hydrochloride Monohydrate</other_name>
    <other_name>Rolapitant Monohydrochloride Monohydrate</other_name>
    <other_name>SCH-619734</other_name>
    <other_name>SCH619734</other_name>
    <other_name>Varubi</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine Sulfate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (rolapitant hydrochloride)</arm_group_label>
    <arm_group_label>Arm II (fosaprepitant dimeglumine)</arm_group_label>
    <other_name>Kyocristine</other_name>
    <other_name>Leurocristine Sulfate</other_name>
    <other_name>Leurocristine, sulfate</other_name>
    <other_name>Oncovin</other_name>
    <other_name>Vincasar</other_name>
    <other_name>Vincosid</other_name>
    <other_name>Vincrex</other_name>
    <other_name>Vincristine, sulfate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with sarcoma which is locally advanced, at high risk for relapse or
             metastatic for whom treatment with doxorubicin plus ifosfamide (AI) or AI and
             vincristine (VAI) is indicated

          -  Patient must have an estimated life expectancy &gt;= 4 months in the opinion of the
             investigators

          -  Male and females of child bearing potential must use acceptable methods of birth
             control which include oral contraceptives, spermicide with either a condom, diaphragm
             or cervical cap, use of an intrauterine device (IUD) or abstinence

               -  Female patients must have a negative pregnancy test at screening

               -  Female patients of childbearing potential must agree to use an acceptable method
                  of birth control (excluding hormonal birth control methods) for 72 hours prior to
                  admission and to continue its use during the study and for at least 30 days after
                  the final dose

               -  Male patients must agree to use an acceptable form of birth control from study
                  day 1 through at least 30 days after the final dose

          -  Absolute neutrophil count (ANC) &gt; 1500/mm^3

          -  Platelet count &gt; 100,000/mm^3

          -  Serum creatinine &lt; 1.5 mg/dL

          -  Serum bilirubin count &lt; 1.5 x upper limit normal (ULN)

          -  Serum glutamic-oxaloacetic transaminase (SGOT) or serum glutamate pyruvate
             transaminase (SGPT) &lt; 2.5 x ULN; for subjects with known liver metastases &lt; 5 x ULN

          -  Karnofsky performance status &gt; 60%

          -  Signed informed consent form

          -  Patients are required to read and understand English to comply with protocol
             requirements

        Exclusion Criteria:

          -  Any current treatment, medical history, or uncontrolled condition, other than
             malignancy, (e.g., alcoholism or signs of alcohol abuse, seizure disorder, medical or
             psychiatric condition) that, in the opinion of the investigator, would confound the
             results of the study or pose any unwarranted risk in administering study drug to the
             subject

          -  Patient has a known hypersensitivity to the administration of any prescribed oral or
             intravenous study medication or metabolite, including but not limited to, a history of
             hypersensitivity to the drugs or their components, severe renal impairment, severe
             bone marrow suppression, or systemic infection

          -  Patient is a woman with a positive urine or serum pregnancy test within 3 days prior
             to study drug administration, is breast-feeding, or is planning to conceive children
             within the projected duration of the study treatment

          -  Patient has taken the anti-emetic agents within the last 48 hours prior to the start
             of treatment with study drug:

               -  5-hydroxytryptamine (HT)3 antagonists (ondansetron, granisetron, dolasetron,
                  tropisetron, etc.); palonosetron is not permitted within 7 days prior to
                  administration of investigational product

               -  Phenothiazines (prochlorperazine, fluphenazine, perphenazine, thiethylperazine,
                  chlorpromazine, etc.)

               -  Benzamides (metoclopramide, alizapride, etc.)

               -  Domperidone

               -  Cannabinoids

               -  Neurokinin (NK)1 antagonist (aprepitant)

               -  Benzodiazepines (lorazepam, alprazolam, etc)

               -  Herbal medications or preparations in doses designed to ameliorate nausea or
                  emesis

          -  Patient has received systemic corticosteroids or sedative antihistamines
             (dimenhydrinate, diphenhydramine, etc.) within 72 hours of day 1 of the study except
             as premedication for chemotherapy (e.g., taxanes); subjects who are receiving inhaled
             steroids for respiratory conditions or topical steroids for skin disorders can be
             enrolled

          -  Patient has symptomatic primary or metastatic central nervous system (CNS) disease

          -  Patient has ongoing vomiting, retching, dry heaves, or clinically significant nausea
             caused by any etiology, or has had such symptoms within 24 hours prior to the start of
             day 1 of the study intervention, or has a history of anticipatory nausea and vomiting

          -  Patient must not have been dosed with test drug or blinded study drug in another
             investigational study within 30 days or 5 half-lives of the biologic activity of the
             test drug, whichever is longer, before the time of first study dose

          -  Patient who is participating in any investigational agent that is not Food and Drug
             Administration (FDA)-approved

          -  Patient has uncontrolled angina, congestive heart failure (New York Heart Association
             &gt; class II or known ejection fraction &lt; 40%), uncontrolled cardiac arrhythmia or
             hypertension, or acute myocardial infarction within 3 months

          -  Prior surgery or radiotherapy (RT) within 2 weeks of study entry

          -  Psychological, social, familial, or geographical reasons that would prevent scheduled
             visits and follow-up
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Saroj Vadhan</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>April 4, 2016</study_first_submitted>
  <study_first_submitted_qc>April 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2016</study_first_posted>
  <last_update_submitted>July 14, 2020</last_update_submitted>
  <last_update_submitted_qc>July 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
    <mesh_term>Isophosphamide mustard</mesh_term>
    <mesh_term>Ondansetron</mesh_term>
    <mesh_term>Fosaprepitant</mesh_term>
    <mesh_term>Aprepitant</mesh_term>
    <mesh_term>Ichthammol</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>8-((1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)methyl)-8-phenyl-1,7-diazaspiro(4,5)decan-2-one</mesh_term>
    <mesh_term>Mesna</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

